SKB264

· Klus Pharma Inc.

Drug timelines are a Plus or Pro feature.

18 regulatory and trial events tracked for SKB264, covering 2025-05-29 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis [Phase 2]